IDL Diagnostics shares Q2 2026 financials and leadership updates
The company reports a substantial revenue increase and improved margins while welcoming Gustav Sten as its new chief executive officer.
See the latest news and media coverage for IDL Diagnostics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish in vitro diagnostics company for cancer and bacterial diseases
idldiagnostics.comLast updated
In short: IDL Diagnostics appointed Gustav Sten as CEO, reported record sales growth, and expanded its presence in Indonesia and China.
The company reports a substantial revenue increase and improved margins while welcoming Gustav Sten as its new chief executive officer.
The meeting approved financial reports, elected board members and authorized a share issue.
He discusses his priorities focusing on commercialization and growth.
He succeeds Anders Hultman and will assume the role on May 28, 2026.
IDL Diagnostics AB has published its financial results for the second quarter and the first half ended June 30, 2026. For the second quarter...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive...
IDL Diagnostics AB is a in vitro diagnostics company, which engages in the monitoring of hematological malignancies, breast cancer, and other solid tumors. Its products...
IDL Diagnostics today announces that the Board of Directors has appointed Gustav Sten as the new Chief Executive Officer (CEO). Gustav Sten will assume the...
Track IDL Diagnostics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to IDL Diagnostics and other trending companies.